nach oben

Journal of Endocrinological Investigation

Erschienen in:

01.02.2020 | Short Review

The functioning side of the pancreas: a review on insulinomas

verfasst von: I. Maggio, V. Mollica, N. Brighi, G. Lamberti, L. Manuzzi, A. D. Ricci, D. Campana

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Insulinomas are a rare type of neuroendocrine tumors, originating in the pancreas, difficult to diagnose and to treat. Due to its rarity, insulinomas are a not well-known pathological entity; thus, the diagnostic process is frequently a medical challenge with many possible differential diagnoses. The diagnostic process varies between non-invasive procedures, such as the fasting test or imaging techniques, and invasive ones. Insulinomas are rarely malignant, but the glycemic imbalance correlated with this tumor can frequently alter the quality of life of the patients and the consequent hypoglycemia can be extremely dangerous. Moreover, insulinomas can be associated with different genetic syndromes, such as Multiple Endocrine Neoplasia 1, accompanied by other specific symptoms. There are many different treatment strategies, depending on the need to control symptoms or control diseases progression, the only curative one being surgery.

Methods and results

We reviewed the evidences present in the literature on insulinomas and reported its main clinical characteristics and management strategies.

Conclusion

The aim of this review of the literature is to present the current knowledge on insulinomas, exploring the main clinical characteristics, the diagnostic tools, and the therapeutic strategies.

Öberg K (2010) Pancreatic endocrine tumors. Semin Oncol 37:594–618PubMed

Guettier JM, Gorden P (2010) Insulin secretion and insulin-producing tumors. Expert Rev Endocrinol Metab. 5(2):217–227PubMedPubMedCentral

Yao JC (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072PubMed

De Herder WW, Niederle B, Scoazec JY et al (2007) Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 84(3):183–188

Tsang YP, Lang BH, Shek TW (2016) Assessing the short- and long-term outcomes after resection of benign insulinoma. ANZ J Surg 86(9):706–710PubMed

Öberg K, Eriksson B (2005) Endorcrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 19(5):753–781PubMed

McLean A (2004) Endoscopic ultrasound in the detection of pancreatic islet cell tumours. Cancer Imaging 4:84–89PubMedPubMedCentral

Mathur A, Gorden P, Libutti SK (2009) Insulinoma. Surg Clin North Am 89(5):1105–1121PubMedPubMedCentral

Okabayashi T, Shima Y, Sumiyoshiet T (2013) Diagnosis and management of insulinoma. World J Gastroenterol 19(6):829–837PubMedPubMedCentral

10.

Jense RT, Berna MJ, Bingham DB et al (2008) Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management and controversies. Cancer 113(7 Suppl):1807–1843

11.

Fung JW, Lam KS (1995) Neurofibromatosis and insulinoma. Postgrad Med J 71:485–486PubMedPubMedCentral

12.

Perren A, Wiesli P, Schmid S et al (2006) Pancreatic endocrine tumors are a rare manifestation of the neurofibromatosis type 1 phenotype: molecular analysis of a malignant insulinoma in a NF-1 patient. Am J Surg Pathol 30:1047–1051PubMed

13.

Coskey RL, Tranquada RE (1965) Insulinoma and multiple neurofibromatosis: report of a case. Metabolism 13:312–318

14.

Kim H, Kerr A, Morehouse H (1995) The association between tuberous sclerosis and insulinoma. Am J Neuroradiol 16:1543–1544PubMed

15.

Larson AM, Hedgire SS, Deshpande V et al (2012) Pancreatic neuroendocrine tumors in patients with tuberous sclerosis complex. Clin Genet 82:558–563PubMed

16.

Boubaddi NE, Imbert Y, Tissot B et al (1997) Secreting insulinoma and Bourneville’s tuberous sclerosis. Gastroenterol Clin Biol 21:343PubMed

17.

Akerstrom G, Hessman O, Hellman P et al (2005) Pancreatic tumours as part of the MEN-1 syndrome. Best Pract Res Clin Gastroenterol 19(5):819–830PubMed

18.

Lam KY, Lo CY (1997) Pancreatic endocrine tumour: a 22-year clinico-pathological experience with morphological, immunohistochemical observation and a review of the literature. Eur J Surg Oncol 23:36–42PubMed

19.

Kenny BD, Sloan JM, Hamilton PW et al (1989) The role of morphometry in predicting prognosis in pancreatic islet cell tumors. Cancer 64:460–465PubMed

20.

Lloyd RV, Osamura R, Kloppel G et al (2017) WHO classification of tumours of endocrine organs, vol 10, 4th edn. IARC Press, Lyon

21.

Rindi G, Falconi M, Klersy C et al (2012) TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 104(10):764–777PubMed

22.

Panzuto F, Boninsegna L, Fazio N et al (2011) Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol 29(17):2372–2377PubMed

23.

Milione M, Maisonneuve P, Spada F (2017) The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories. Neuroendocrinology 104:85–93PubMed

24.

Falconi M, Eriksson B, Kaltsas G et al (2016) ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 103(2):153–171PubMedPubMedCentral

25.

Rindi G, Klöppel G, Alhman H et al (2006) TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449(4):395–401PubMedPubMedCentral

26.

Sobin L, Gospodarowicz M, Wittekind C (2009) TNM Classification of Malignant Tumours, 7th edn. Wiley Blackwell, Bognor Regis

27.

Edge SB et al (2010) AJCC cancer staging manual. Springer, New York

28.

Luo G, Javed A, Strosberg JR et al (2017) Modified staging classification for pancreatic neuroendocrine tumors on the basis of the American joint committee on cancer and european neuroendocrine tumor society systems. J Clin Oncol 35(3):274–280PubMed

29.

Wiedenmann B, Rudiger W, Heinz B et al (1988) Identification of gastroenteropancreatic neuroendocrine cells in normal and neoplastic human tissue with antibodies against Synaptophysin, Chromogranin A, Secretogranin I (Chromogranin B), and Secretogranin II. Gastroenterology 95:1364–1374PubMed

30.

Körner M, Christ E, Wild D et al (2012) Glucagon-like peptide-1 receptor over-expression in cancer and its impact on clinical applications. Front Endocrinol 3:158

31.

Luo Y, Pan Q, Yao S et al (2016) Glucagon-Like peptide-1 receptor PET/CT with 68 Ga-NOTAExendin-4 for detecting localized insulinoma: a prospective cohort study. J Nucl Med 57(5):715–720PubMedPubMedCentral

32.

Portela-Gomes GM, Stridsberg M, Grimelius L et al (2007) Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas—predominance of receptor subtype 4. Endocr Pathol 18:79–85PubMed

33.

Cao Y, Gao Z, Li L et al (2013) Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1. Nat Commun 4:2810PubMed

34.

Alkatout I, Friemel J, Sitek B et al (2015) Novel prognostic markers revealed by a proteomic approach separating benign from malignant insulinomas. Mod Pathol 28(1):69–79PubMed

35.

Kittah NE, Vella A (2017) Pathogenesis and management of hypoglycemia. Eur J Endocrinol 177:37–47

36.

Grant CS (2005) Insulinoma. Best Pract Res Clin Gastroenterol 19(5):783–798PubMed

37.

Shin JJ, Gorden P, Libutti SK (2010) Insulinoma: pathophysiology, localization and management. Future Oncol 6(2):229–237PubMedPubMedCentral

38.

Peltola E, Hannula P, Huhtala H et al (2018) Characteristics and outcomes of 79 patients with an insulinoma: a nationwide retrospective study in Finland. Int J Endocrinol 2018:2059481PubMedPubMedCentral

39.

Placzkowski KA (2009) Secular trends in the presentation and management of functioning insulinoma at the mayo clinic, 1987–2007. J Clin Endocrinol Metab 94(4):1069–1073PubMed

40.

Toaiari M, Davì MV, Dalle Carbonare L et al (2013) Presentation, diagnostic features and glucose handling in a monocentric series of insulinomas. J Endocrinol Invest 36:753–758PubMed

41.

De Herder WW (2007) Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 21(1):33–41PubMed

42.

Cryer PE, Axelrod L, Grossman AB et al (2009) Evaluation and management of adult hypoglycemic disorders: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 94:709–728PubMed

43.

Metz DC, Jensen RT (2008) Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 135(5):1469–1492PubMedPubMedCentral

44.

An L, Li W, Yao KC et al (2011) Assessment of contrast-enhanced ultrasonography in diagnosis and preoperative localization of insulinoma. Eur J Radiol 80:675–680PubMed

45.

Wang H, Ba Y, Xing Q, Du JL (2018) Diagnostic value of endoscopic ultrasound for insulinoma localization: a systematic review and meta-analysis. PLoS One 13(10):e0206099PubMedPubMedCentral

46.

Lee LS (2010) Diagnosis of pancreatic neuroendocrine tumors and the role of endoscopic ultrasound. Gastroenterol Hepatol 6(8):520–522

47.

Wong M, Isa SH, Zahiah M et al (2007) Intraoperative ultrasound with palpation is still superior to intra-arterial calcium stimulation test in localising insulinoma. World J Surg 31:586–592PubMed

48.

Kann PH, Moll R, Bartsch D et al (2017) Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNA) in insulinomas: indications and clinical relevance in a single investigator cohort of 47 patients. Endocrine 56(1):158–163PubMed

49.

Luigiano C, Ferrara F, Morace C et al (2012) Endoscopic tattooing of gastrointestinal and pancreatic lesions. Adv Ther 29(10):864–873PubMed

50.

Challis BG, Powlson AS, Casey RT et al (2017) Adult-onset hyperinsulinaemic hypoglycaemia in clinical practice: diagnosis, aetiology and management. Endocrine Connect 6:540–548

51.

Burghardt L, Meier JJ, Uhl W et al (2019) Importance of localization of insulinomas—a systematic analysis. J Hepatobiliary Pancreat Sci. https://doi.org/10.1002/jhbp.642 CrossRefPubMed

52.

Fidler JL, Fletcher JG, Reading CC et al (2003) Preoperative detection of pancreatic insulinomas on multiphasic helical CT. Am J Roentgenol 181:775–780

53.

Gouya H, Vignaux O, Augui J et al (2003) CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. Am J Roentgenol 181:987–992

54.

Antwi K, Fani M, Heye T et al (2018) Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study. Eur J Nucl Med Mol Imaging 45(13):2318–2327PubMed

55.

Luo Y, Yu M, Pan Q et al (2015) 68Ga-NOTA-exendin-4 PET/CT in detection of occult insulinoma and evaluation of physiological uptake. Eur J Nucl Med Mol Imaging 42:531–532PubMed

56.

Sharma P, Arora S, Dhull VS et al (2015) Evaluation of Ga-DOTANOC PET/CT imaging in a large exclusive population of pancreatic neuroendocrine tumors. Abdom Imaging 40(2):299–309PubMed

57.

Nockel P, Babic B, Millo C et al (2017) Localization of insulinoma using 68 Ga-DOTATATE PET/CT scan. J Clin Endocrinol Metab 102(1):195–199PubMed

58.

Sharma P, Arora S, Karunanithi S et al (2016) Somatostatin receptor based PET/CT imaging with 68 Ga- DOTA-Nal3-Octreotide for localisation of clinically and biochemically suspected insulinoma. Q J Nucl Med Mol Imagin 60(1):69–76

59.

Brown E, Watkin D, Evans J et al (2017) Multidisciplinary management of refractory insulinomas. Clin Endocrinol 88(5):1–10

60.

Wild D, Christ E, Caplin ME et al (2011) Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med 52:1073–1078PubMed

61.

Ambrosini V, Campana D, Nanni C et al (2015) 68Ga DOTANOC PET/CT detects primary malignant insulinoma. Clin Nucl Med 40(2):e132–e133PubMed

62.

Doppman JL (1995) Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Ann Intern Med 123:269–273PubMed

63.

Tseng LM, Chen JY, Won JG et al (2007) The role of intra-arterial calcium stimulation test with hepatic venous sampling (IACS) in the management of occult insulinomas. Ann Surg Oncol 4(7):2121–2127

64.

Guettier JM, Kam A, Chang R et al (2009) Localization of insulinomas to regions of the pancreas by intraarterial calcium stimulation: the NIH experience. J Clin Endocrinol Metab 94(4):1074–1080PubMedPubMedCentral

65.

Christ E, Wild D, Ederer S et al (2013) Glucagon-like peptide-1 receptor imaging for the localization of insulinomas: a prospective multicentre imaging study. Lancet Diabetes Endocrinol 1:115–122PubMed

66.

Patti ME, McMahon G, Mun EC et al (2005) Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 48:2236–2240PubMed

67.

Murad MH, Coto-Yglesias F, Wang AT et al (2009) Clinical review: drug-induced hypoglycemia: a systematic review. J Clin Endocrinol Metab 94:741–745PubMed

68.

Celli R, Tang LH, Cai G et al (2019) proinsulin expressing neuroendocrine tumors of the pancreas: an underrecognized entity. Pancreas 48(1):55–59PubMed

69.

Murtha TD, Lupsa BC, Majumdar S et al (2017) A systematic review of proinsulin-secreting pancreatic neuroendocrine tumors. J Gastrointest Surg 21(8):1335–1341PubMed

70.

Modlin IM, Gustafsson BI, Moss SF et al (2010) Chromogranin A—biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 7:2427–2443

71.

Kanakis G, Kaltsas G (2012) Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best Pract Res Clin Gastroenterol 26:791–802PubMed

72.

Baudin E (2007) Gastroenteropancreatic endocrine tumors: clinical characterization before therapy. Nat Clin Pract Endocrinol Metab 3:228–239PubMed

73.

Campana D, Nori F, Piscitelli L et al (2007) Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 25:1967–1973PubMed

74.

Han X (2015) The value of serum Chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases. Eur J Gastroenterol Hepatol 27(5):527PubMed

75.

Antonakis PT, Ashrafian H, Martinez-Isla A (2015) Pancreatic insulinomas: laparoscopic management. World J Gastrointest Endosc 7(16):1197–1207PubMedPubMedCentral

76.

Kulke MH, Anthony LB, Bushnell DL et al (2010) NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 39:735–752PubMedPubMedCentral

77.

Abbou B, Boujaoude J (2008) Occult sporadic insulinoma: localization and surgical strategy. World J Gastroenterol 14(5):657–665

78.

Danforth DN Jr, Gorden P, Brennan MF (1984) Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery. Surgery 96:1027–1037PubMed

79.

Levy MJ, Thompson GB, Topazian MD et al (2012) US-guided ethanol ablation of insulinomas: a new treatment option. Gastrointest Endosc 75:200–206PubMed

80.

Lakhtakia S, Ramchandani M, Galasso D et al (2016) EUS-guided radiofrequency ablation for management of pancreatic insulinoma by using a novel needle electrode (with videos). Gastrointest Endosc 83(1):234–239PubMed

81.

Oberg K (2018) Management of functional neuroendocrine tumors of the pancreas. Gland Surg 7(1):20–27PubMedPubMedCentral

82.

Niitsu Y, Minami I, Izumiyama H et al (2019) Clinical outcomes of 20 Japanese patients with insulinoma treated with diazoxide. Endocr J 66(2):149–155PubMed

83.

Stehouwer CD, Lems WF, Fischer HR et al (1989) Malignant insulinoma: is combined treatment with verapamil and the long-acting somatostatin analogue octreotide (SMS 201–995) more effective than single therapy with either drug? Neth J Med 35(1–2):86–94PubMed

84.

Matej A, Bujwid H, Wroński J (2016) Glycemic control in patients with insulinoma. Hormones 15(4):489–499PubMed

85.

Ong GS, Henley DE, Hurley D et al (2010) Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma. Eur J Endocrinol 162:1001–1008PubMed

86.

Tirosh A, Stemmer SM, Solomonov E et al (2016) Pasireotide for malignant insulinoma. Hormones 15:271–276PubMed

87.

Hendren NS, Panach K, Brown TJ et al (2018) Pasireotide for the treatment of refractory hypoglycemia from malignant insulinoma. Clin Endocrinol 88(2):341–343

88.

Cives M, Kunz PL, Morse B et al (2015) Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocr Relat Cancer 22:1–9PubMed

89.

Kulke MH, Bergsland EK, Yao JC (2009) Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 360:195–197PubMed

90.

Lamberti G, Ceccarelli C, Brighi N et al (2017) Determination of mammalian target of rapamycin hyperactivation as prognostic factor in well-differentiated neuroendocrine tumors. Gastroenterol Res Pract 2017:7872519. https://doi.org/10.1155/2017/7872519 CrossRefPubMedPubMedCentral

91.

Pavel ME, Hainsworth JD, Baudin E et al (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378:2005–2012PubMed

92.

Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523PubMedPubMedCentral

93.

Yao JC, Fazio N, Singh S et al (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387:968–977PubMed

94.

Bourcier ME, Sherrod A, DiGuardo M et al (2009) Successful control of intractable hypoglycemia using rapamycin in an 86-year- old man with a pancreatic insulin-secreting islet cell tumor and metastases. J Clin Endocrinol Metab 94:3157–3162PubMed

95.

Bernard V, Lombard-Bohas C, Taquet MC et al (2013) Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia. Eur J Endocrinol 168:665–674PubMed

96.

Asayama M, Yamada-Murano T, Hara H et al (2014) Everolimus dramatically improves glycemic control in unresectable metastatic insulinoma: a case report. Jpn J Clin Oncol 44(2):186–190PubMed

97.

Ferrer-García J, Tolosa-Torréns M, Hernando-Meliá C et al (2011) Everolimus resolving hypoglycemia, producing hyperglycemia, and necessitating insulin use in a patient with diabetes and nonresectable malignant insulinoma. Endocr Pract 17:17–20

98.

Suzuki L, Miyatsuka T, Himuro M et al (2018) Everolimus directly suppresses insulin secretion independently of cell growth inhibition. J Endocr Soc 2(7):589–596PubMedPubMedCentral

99.

Baratelli C, Brizzi MP, Tampellini M et al (2014) Intermittent everolimus administration for malignant insulinoma. Endocrinol Diabetes Metab Case Rep. https://doi.org/10.1530/EDM-14-0047 CrossRefPubMedPubMedCentral

100.

Moertel CG, Hanley JA, Johnson LA (1980) Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303:1189–1194PubMed

101.

Moertel CG, Lefkopoulo M, Lipsitz S et al (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519–523PubMed

102.

Cheng PN, Saltz LB (1999) Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86:944–948PubMed

103.

Kouvaraki MA, Ajani JA, Hoff P et al (2004) Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22:4762–4771PubMed

104.

Koumarianou A, Kaltsas G, Kulke MH et al (2015) Temozolomide in advanced neuroendocrine neoplasms: pharmacological and clinical aspects. Neuroendocrinology 101:274–288PubMed

105.

Strosberg JR, Fine RL, Choi J et al (2011) First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117:268–275PubMed

106.

Kulke MH, Hornick JL, Frauenhoffer C et al (2009) O⁶-Methylguanine DNA methyltransferase deficiency and response to Temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15(1):338–345PubMedPubMedCentral

107.

Campana D, Walter T, Pusceddu S et al (2018) Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study. Endocrine 60:490–498PubMed

108.

Cives M, Ghayouri M, Morse B et al (2016) Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer 23:759–767PubMed

109.

Mitry E, Baudin E, Ducreux M et al (1999) Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81:1351–1355PubMedPubMedCentral

110.

Moertel CG, Kvols LK, O’Connell MJ et al (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68:227–232PubMed

111.

Strosberg J, El-Haddad G, Wolin E et al (2017) Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med 376:125–135PubMedPubMedCentral

112.

Pavel M, O’Toole D, Costa F et al (2016) Consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103(2):172–185PubMed

113.

Brabander T, van der Zwan WA, Teunissen JJM et al (2017) Long-term efficacy, survival, and safety of [177Lu-DOTA0, Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res 23(16):4617–4624PubMed

114.

Magalhães D, Sampaio IL, Ferreira G et al (2019) Peptide receptor radionuclide therapy with (177)Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review. J Endocrinol Investig 42(3):249–260

115.

Van Schaik E, van Vliet EI, Feelders RA et al (2011) Improved control of severe hypoglycemia in patients with malignant insulinomas by peptide receptor radionuclide therapy. J Clin Endocrinol Metab 96:3381–3389PubMed

116.

Zandee WT, Brabander T, Blazˇevic A (2019) Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab 104(4):1336–1344PubMed

Titel: The functioning side of the pancreas: a review on insulinomas
verfasst von: I. Maggio
V. Mollica
N. Brighi
G. Lamberti
L. Manuzzi
A. D. Ricci
D. Campana
Publikationsdatum: 01.02.2020
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 2/2020
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-019-01091-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

The functioning side of the pancreas: a review on insulinomas

Abstract

Purpose

Methods and results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Chronische Verstopfung: „Versuchen Sie es mit grünen Kiwis!“

So häufig greift rheumatoide Arthritis auf Organe über

Blutdrucksenkung könnte Uterusmyome verhindern

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Update Innere Medizin

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose

Methods and results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Immunohistochemical analysis of human orbital tissue in Graves’ orbitopathy

Could Amedeo Modigliani have painted a thyroid swelling?

A broad range of symptoms in allgrove syndrome: single center experience in Southeast Anatolia

Genetic interaction analysis of VEGF-A rs3025039 and VEGFR-2 rs2071559 identifies a genetic profile at higher risk to develop nodular goiter

The clinical phenotype of Graves’ disease occurring as an isolated condition or in association with other autoimmune diseases

Untreated adult GH deficiency is not associated with the development of metabolic risk factors: a long-term observational study

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Chronische Verstopfung: „Versuchen Sie es mit grünen Kiwis!“

So häufig greift rheumatoide Arthritis auf Organe über

Blutdrucksenkung könnte Uterusmyome verhindern

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Update Innere Medizin